Figure 4.
Subgroup analysis based on medicine type used for remission outcome. Abciximab: 12 studies with an average remission rate of 92% and p < .001; I2 = 66.28. Tirofiban: Four studies with an average remission rate of 86% and p < .00; I2 = 77.48. Tirofiban and abciximab: One study with an average remission rate of 97% and p: NA. Eptifibatide: Two studies with an average remission rate of 82% and p < .001; I2 = 0.
